| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 49 | 2020 | 312 | 9.610 |
Why?
|
| Insulin | 30 | 2020 | 346 | 5.830 |
Why?
|
| Insulin Resistance | 21 | 2020 | 449 | 3.550 |
Why?
|
| Brain | 28 | 2020 | 930 | 2.760 |
Why?
|
| Cognition Disorders | 18 | 2015 | 390 | 2.740 |
Why?
|
| Hypoglycemic Agents | 11 | 2015 | 177 | 2.610 |
Why?
|
| Cognition | 18 | 2018 | 526 | 2.380 |
Why?
|
| Apolipoprotein E4 | 13 | 2018 | 58 | 2.370 |
Why?
|
| Dementia | 14 | 2019 | 234 | 1.980 |
Why?
|
| Neuropsychological Tests | 21 | 2019 | 379 | 1.700 |
Why?
|
| Memory | 12 | 2013 | 187 | 1.630 |
Why?
|
| Aging | 12 | 2014 | 881 | 1.490 |
Why?
|
| Peptide Fragments | 11 | 2017 | 423 | 1.450 |
Why?
|
| Glucose | 8 | 2015 | 164 | 1.350 |
Why?
|
| Aged | 53 | 2019 | 9515 | 1.250 |
Why?
|
| Humans | 88 | 2020 | 29220 | 1.190 |
Why?
|
| Lipid Metabolism | 3 | 2015 | 100 | 1.040 |
Why?
|
| Female | 55 | 2019 | 18241 | 0.970 |
Why?
|
| Inflammation | 4 | 2012 | 508 | 0.970 |
Why?
|
| Double-Blind Method | 18 | 2019 | 504 | 0.910 |
Why?
|
| Dementia, Vascular | 2 | 2015 | 13 | 0.890 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 116 | 0.890 |
Why?
|
| Male | 49 | 2019 | 17876 | 0.850 |
Why?
|
| Diet, Fat-Restricted | 2 | 2012 | 30 | 0.850 |
Why?
|
| Aged, 80 and over | 28 | 2019 | 3728 | 0.780 |
Why?
|
| Genotype | 8 | 2013 | 735 | 0.780 |
Why?
|
| Animals | 25 | 2020 | 7302 | 0.740 |
Why?
|
| Apolipoproteins E | 8 | 2014 | 97 | 0.730 |
Why?
|
| Exercise | 3 | 2010 | 595 | 0.690 |
Why?
|
| Cerebral Cortex | 4 | 2012 | 141 | 0.690 |
Why?
|
| Administration, Intranasal | 9 | 2019 | 30 | 0.690 |
Why?
|
| Amnesia | 2 | 2011 | 10 | 0.680 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 981 | 0.650 |
Why?
|
| Thiazolidinediones | 4 | 2010 | 47 | 0.650 |
Why?
|
| Glucose Intolerance | 2 | 2010 | 44 | 0.640 |
Why?
|
| Sex Characteristics | 3 | 2016 | 167 | 0.620 |
Why?
|
| Diabetes Mellitus | 7 | 2013 | 370 | 0.620 |
Why?
|
| Postmenopause | 5 | 2015 | 397 | 0.620 |
Why?
|
| Exercise Therapy | 2 | 2010 | 229 | 0.610 |
Why?
|
| Memory Disorders | 3 | 2008 | 61 | 0.610 |
Why?
|
| Dietary Fats | 2 | 2015 | 108 | 0.600 |
Why?
|
| Nootropic Agents | 1 | 2017 | 13 | 0.590 |
Why?
|
| Diet | 3 | 2013 | 356 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2018 | 1383 | 0.550 |
Why?
|
| Estradiol | 3 | 2011 | 118 | 0.530 |
Why?
|
| Insulin, Long-Acting | 1 | 2015 | 3 | 0.520 |
Why?
|
| Insulysin | 3 | 2006 | 6 | 0.510 |
Why?
|
| Prediabetic State | 2 | 2015 | 55 | 0.500 |
Why?
|
| Oxidative Stress | 3 | 2013 | 223 | 0.490 |
Why?
|
| Middle Aged | 22 | 2019 | 10872 | 0.480 |
Why?
|
| Hydrocortisone | 2 | 2011 | 61 | 0.460 |
Why?
|
| tau Proteins | 5 | 2017 | 38 | 0.450 |
Why?
|
| Analysis of Variance | 7 | 2015 | 454 | 0.440 |
Why?
|
| Glycemic Index | 1 | 2012 | 14 | 0.440 |
Why?
|
| Verbal Behavior | 2 | 2012 | 9 | 0.430 |
Why?
|
| Mental Recall | 3 | 2015 | 52 | 0.420 |
Why?
|
| Fatty Liver | 1 | 2012 | 66 | 0.420 |
Why?
|
| Treatment Outcome | 11 | 2018 | 3108 | 0.410 |
Why?
|
| Physical Fitness | 2 | 2010 | 120 | 0.410 |
Why?
|
| Estrogens | 2 | 2015 | 162 | 0.400 |
Why?
|
| Food, Formulated | 1 | 2011 | 10 | 0.400 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 21 | 0.400 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 26 | 0.400 |
Why?
|
| Amyloid | 2 | 2014 | 17 | 0.400 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2015 | 182 | 0.390 |
Why?
|
| Longitudinal Studies | 8 | 2015 | 725 | 0.360 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 36 | 0.350 |
Why?
|
| Motor Activity | 1 | 2012 | 311 | 0.350 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 59 | 0.350 |
Why?
|
| Residence Characteristics | 1 | 2011 | 181 | 0.350 |
Why?
|
| Octreotide | 1 | 2009 | 3 | 0.340 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 17 | 0.340 |
Why?
|
| Gastrointestinal Agents | 1 | 2009 | 6 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 126 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2015 | 641 | 0.340 |
Why?
|
| Somatostatin | 1 | 2009 | 10 | 0.340 |
Why?
|
| Energy Metabolism | 4 | 2017 | 139 | 0.340 |
Why?
|
| Norepinephrine | 2 | 2006 | 73 | 0.330 |
Why?
|
| Brain Injuries | 1 | 2009 | 94 | 0.320 |
Why?
|
| Neurodegenerative Diseases | 2 | 2006 | 13 | 0.310 |
Why?
|
| Time Factors | 6 | 2018 | 2003 | 0.300 |
Why?
|
| Hippocampus | 2 | 2012 | 185 | 0.290 |
Why?
|
| Central Nervous System | 1 | 2006 | 29 | 0.290 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2114 | 0.290 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2006 | 17 | 0.280 |
Why?
|
| Area Under Curve | 3 | 2015 | 85 | 0.280 |
Why?
|
| Hyperinsulinism | 1 | 2005 | 12 | 0.270 |
Why?
|
| Brain Chemistry | 2 | 2013 | 30 | 0.270 |
Why?
|
| Cytokines | 2 | 2012 | 243 | 0.270 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 43 | 0.270 |
Why?
|
| Body Mass Index | 4 | 2014 | 867 | 0.260 |
Why?
|
| Severity of Illness Index | 6 | 2014 | 864 | 0.260 |
Why?
|
| Blood Glucose | 4 | 2013 | 467 | 0.250 |
Why?
|
| Positron-Emission Tomography | 4 | 2018 | 172 | 0.250 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2004 | 3 | 0.250 |
Why?
|
| Aptitude | 1 | 2004 | 2 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Automobile Driving | 1 | 2004 | 24 | 0.240 |
Why?
|
| Memantine | 2 | 2014 | 4 | 0.240 |
Why?
|
| Lewy Body Disease | 2 | 2017 | 5 | 0.240 |
Why?
|
| Vitamin E | 2 | 2014 | 21 | 0.230 |
Why?
|
| Glucocorticoids | 1 | 2005 | 149 | 0.230 |
Why?
|
| Mental Status Schedule | 3 | 2015 | 24 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Growth Hormone-Releasing Hormone | 2 | 2013 | 7 | 0.230 |
Why?
|
| Triglycerides | 1 | 2004 | 214 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Risk Factors | 7 | 2018 | 3550 | 0.220 |
Why?
|
| Alleles | 4 | 2017 | 251 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Antioxidants | 2 | 2014 | 114 | 0.220 |
Why?
|
| Executive Function | 3 | 2012 | 54 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 80 | 0.210 |
Why?
|
| Obesity | 2 | 2007 | 1068 | 0.210 |
Why?
|
| Prevalence | 4 | 2019 | 907 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 3 | 2018 | 48 | 0.200 |
Why?
|
| Cholesterol | 2 | 2015 | 230 | 0.200 |
Why?
|
| Body Fat Distribution | 2 | 2012 | 34 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2018 | 1695 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2011 | 56 | 0.190 |
Why?
|
| Body Weight | 2 | 2013 | 290 | 0.190 |
Why?
|
| Naproxen | 2 | 2011 | 8 | 0.180 |
Why?
|
| Glucose Tolerance Test | 3 | 2015 | 125 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2011 | 65 | 0.180 |
Why?
|
| Sulfonamides | 2 | 2011 | 65 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Age Factors | 3 | 2015 | 1110 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 71 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 481 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 1219 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 240 | 0.160 |
Why?
|
| Diabetes Complications | 2 | 2013 | 171 | 0.160 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2015 | 125 | 0.160 |
Why?
|
| Heart Rate | 2 | 2010 | 315 | 0.160 |
Why?
|
| Methylphenidate | 1 | 2018 | 36 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 93 | 0.150 |
Why?
|
| United States | 5 | 2018 | 3648 | 0.150 |
Why?
|
| F2-Isoprostanes | 2 | 2009 | 20 | 0.150 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 10 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2011 | 478 | 0.150 |
Why?
|
| Nerve Degeneration | 1 | 2017 | 10 | 0.150 |
Why?
|
| Benzopyrans | 1 | 2017 | 7 | 0.150 |
Why?
|
| Affect | 3 | 2012 | 63 | 0.150 |
Why?
|
| Boron Compounds | 1 | 2017 | 8 | 0.150 |
Why?
|
| Fluorine Radioisotopes | 1 | 2017 | 21 | 0.150 |
Why?
|
| Neostriatum | 1 | 2017 | 21 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 74 | 0.150 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 137 | 0.150 |
Why?
|
| Neuroblastoma | 1 | 2017 | 32 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 53 | 0.140 |
Why?
|
| Space Perception | 2 | 2015 | 26 | 0.140 |
Why?
|
| Interleukin-6 | 2 | 2009 | 225 | 0.140 |
Why?
|
| Hyperglycemia | 2 | 2014 | 82 | 0.140 |
Why?
|
| Organ Size | 1 | 2017 | 196 | 0.140 |
Why?
|
| Synapses | 1 | 2017 | 85 | 0.140 |
Why?
|
| In Situ Hybridization | 3 | 2006 | 35 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2013 | 81 | 0.140 |
Why?
|
| Stilbenes | 1 | 2015 | 25 | 0.130 |
Why?
|
| Neuroglia | 2 | 2012 | 29 | 0.130 |
Why?
|
| Psychomotor Disorders | 1 | 2015 | 4 | 0.130 |
Why?
|
| Attention | 3 | 2004 | 84 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2011 | 667 | 0.130 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 59 | 0.120 |
Why?
|
| Autopsy | 2 | 2017 | 37 | 0.120 |
Why?
|
| Models, Biological | 2 | 2007 | 373 | 0.120 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 25 | 0.120 |
Why?
|
| Dopamine Agents | 1 | 2014 | 19 | 0.120 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 129 | 0.120 |
Why?
|
| Disease Progression | 4 | 2019 | 572 | 0.120 |
Why?
|
| Homeostasis | 2 | 2014 | 127 | 0.120 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 26 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2005 | 281 | 0.110 |
Why?
|
| Vasodilation | 1 | 2013 | 87 | 0.110 |
Why?
|
| Incidence | 3 | 2019 | 1123 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 74 | 0.110 |
Why?
|
| Hormones | 1 | 2012 | 19 | 0.110 |
Why?
|
| Apolipoprotein C-I | 1 | 2012 | 4 | 0.110 |
Why?
|
| Venoms | 1 | 2012 | 2 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1366 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 519 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 152 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 298 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2012 | 36 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2013 | 119 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2005 | 514 | 0.100 |
Why?
|
| Microglia | 1 | 2012 | 48 | 0.100 |
Why?
|
| Energy Intake | 1 | 2012 | 120 | 0.100 |
Why?
|
| Temporal Lobe | 1 | 2012 | 41 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 29 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 546 | 0.100 |
Why?
|
| Immunoassay | 1 | 2011 | 13 | 0.100 |
Why?
|
| Peptides | 1 | 2012 | 118 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 21 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 20 | 0.100 |
Why?
|
| Spinal Puncture | 1 | 2011 | 20 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 33 | 0.100 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2011 | 7 | 0.100 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2010 | 4 | 0.100 |
Why?
|
| Lipids | 1 | 2012 | 211 | 0.100 |
Why?
|
| Hypothalamus | 1 | 2010 | 18 | 0.100 |
Why?
|
| Delirium | 1 | 2011 | 13 | 0.100 |
Why?
|
| Homozygote | 2 | 2017 | 57 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2011 | 42 | 0.090 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 95 | 0.090 |
Why?
|
| Neoplasms | 1 | 2016 | 612 | 0.090 |
Why?
|
| Calcium | 1 | 2012 | 297 | 0.090 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 12 | 0.090 |
Why?
|
| PPAR gamma | 2 | 2010 | 45 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2010 | 68 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 466 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 36 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 494 | 0.090 |
Why?
|
| Thiazoles | 2 | 2014 | 32 | 0.090 |
Why?
|
| Geriatrics | 1 | 2011 | 94 | 0.090 |
Why?
|
| Community Health Planning | 1 | 2009 | 9 | 0.090 |
Why?
|
| Thinking | 1 | 2009 | 6 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 138 | 0.090 |
Why?
|
| Neurofibrillary Tangles | 1 | 2009 | 7 | 0.090 |
Why?
|
| Exercise Test | 1 | 2010 | 194 | 0.090 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 26 | 0.080 |
Why?
|
| Cerebral Angiography | 1 | 2009 | 51 | 0.080 |
Why?
|
| Acetylcholine | 1 | 2009 | 47 | 0.080 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 110 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2016 | 860 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 375 | 0.080 |
Why?
|
| Depression | 1 | 2011 | 383 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 638 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 711 | 0.070 |
Why?
|
| Mass Screening | 1 | 2009 | 225 | 0.070 |
Why?
|
| Adult | 4 | 2016 | 8468 | 0.070 |
Why?
|
| Psychomotor Performance | 2 | 2004 | 97 | 0.070 |
Why?
|
| Japan | 1 | 2006 | 15 | 0.070 |
Why?
|
| Risk | 2 | 2018 | 290 | 0.070 |
Why?
|
| Mice | 4 | 2017 | 2372 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 73 | 0.070 |
Why?
|
| Prealbumin | 1 | 2005 | 8 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2005 | 33 | 0.070 |
Why?
|
| Saliva | 1 | 2005 | 36 | 0.070 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2006 | 110 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 20 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 70 | 0.070 |
Why?
|
| Macaca | 1 | 2005 | 25 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 200 | 0.060 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 11 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 12 | 0.060 |
Why?
|
| Receptor, Insulin | 1 | 2004 | 9 | 0.060 |
Why?
|
| Ketone Bodies | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2004 | 24 | 0.060 |
Why?
|
| Mental Competency | 1 | 2004 | 5 | 0.060 |
Why?
|
| Orientation | 1 | 2004 | 24 | 0.060 |
Why?
|
| Problem Solving | 1 | 2004 | 28 | 0.060 |
Why?
|
| Language | 1 | 2004 | 44 | 0.060 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2003 | 6 | 0.060 |
Why?
|
| Dihydrotestosterone | 1 | 2003 | 3 | 0.060 |
Why?
|
| Hypogonadism | 1 | 2003 | 5 | 0.060 |
Why?
|
| Life Style | 1 | 2006 | 364 | 0.060 |
Why?
|
| Androgens | 1 | 2003 | 22 | 0.060 |
Why?
|
| Testosterone | 1 | 2003 | 48 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2014 | 29 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2007 | 1313 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1425 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 710 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 249 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 26 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 92 | 0.040 |
Why?
|
| Haplorhini | 1 | 2017 | 64 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 533 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2012 | 2027 | 0.040 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 64 | 0.040 |
Why?
|
| Administration, Cutaneous | 2 | 2011 | 107 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2017 | 55 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 50 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2016 | 30 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2016 | 12 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 160 | 0.040 |
Why?
|
| Primates | 1 | 2017 | 101 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 180 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2017 | 195 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 38 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2015 | 89 | 0.030 |
Why?
|
| Societies | 1 | 2014 | 4 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 17 | 0.030 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2015 | 11 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 37 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 681 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2014 | 25 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 632 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 50 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 464 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 130 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 33 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 64 | 0.030 |
Why?
|
| Gyrus Cinguli | 1 | 2013 | 22 | 0.030 |
Why?
|
| Models, Animal | 1 | 2014 | 160 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2013 | 68 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2013 | 45 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 95 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 273 | 0.030 |
Why?
|
| Educational Status | 1 | 2013 | 165 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Poly I-C | 1 | 2012 | 4 | 0.030 |
Why?
|
| Veterans | 1 | 2013 | 50 | 0.030 |
Why?
|
| Kidney | 1 | 2017 | 486 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2012 | 37 | 0.030 |
Why?
|
| Caregivers | 1 | 2014 | 94 | 0.030 |
Why?
|
| Astrocytes | 1 | 2012 | 49 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2012 | 111 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 820 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2018 | 700 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 788 | 0.030 |
Why?
|
| Sleep | 1 | 2012 | 87 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2013 | 154 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2011 | 141 | 0.020 |
Why?
|
| Tape Recording | 1 | 2011 | 6 | 0.020 |
Why?
|
| Educational Technology | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 11 | 0.020 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 25 | 0.020 |
Why?
|
| Nasopharyngitis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2011 | 24 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2010 | 9 | 0.020 |
Why?
|
| Body Composition | 1 | 2012 | 365 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 188 | 0.020 |
Why?
|
| Rural Health Services | 1 | 2011 | 27 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2010 | 9 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 73 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 67 | 0.020 |
Why?
|
| Edema | 1 | 2010 | 30 | 0.020 |
Why?
|
| Teaching | 1 | 2011 | 55 | 0.020 |
Why?
|
| Indans | 1 | 2010 | 25 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 118 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 800 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 129 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 439 | 0.020 |
Why?
|
| Piperidines | 1 | 2010 | 125 | 0.020 |
Why?
|
| Iodine Isotopes | 1 | 2009 | 1 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2009 | 9 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 17 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 493 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2009 | 61 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2011 | 181 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 913 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2007 | 107 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
|
| Neurons | 1 | 2010 | 394 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 546 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 747 | 0.020 |
Why?
|
| Metyrapone | 1 | 2006 | 1 | 0.020 |
Why?
|
| Corticosterone | 1 | 2006 | 9 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 24 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1019 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 34 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 162 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 1604 | 0.020 |
Why?
|
| Field Dependence-Independence | 1 | 2004 | 1 | 0.020 |
Why?
|
| Discrimination Learning | 1 | 2004 | 20 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2006 | 264 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 39 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 224 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2003 | 8 | 0.010 |
Why?
|
| Reaction Time | 1 | 2004 | 121 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 246 | 0.010 |
Why?
|
| Child | 1 | 2004 | 2221 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 3265 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 3122 | 0.010 |
Why?
|